Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ELVN NASDAQ:KOD NASDAQ:MLYS NASDAQ:ZSQR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeELVNEnliven Therapeutics$34.71-2.2%$41.44$14.78▼$48.53$2.11B0.29724,930 shs1.08 million shsKODKodiak Sciences$31.05-9.1%$39.92$3.43▼$47.84$1.94B2.21638,104 shs1.45 million shsMLYSMineralys Therapeutics$23.69-5.4%$27.95$12.59▼$47.65$1.95B0.571.55 million shs4.18 million shsZSQRCoeptis Therapeutics$10.12-7.1%$11.93$6.80▼$21.41$520.48M-0.22238,395 shs230,956 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceELVNEnliven Therapeutics-2.20%-12.28%-15.75%+17.90%+55.72%KODKodiak Sciences-9.10%-15.42%-32.34%+24.90%+682.12%MLYSMineralys Therapeutics-5.43%-24.79%-21.35%-10.91%+52.64%ZSQRCoeptis Therapeutics-7.07%+8.70%-27.66%-23.28%+6.75%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeELVNEnliven Therapeutics$34.71-2.2%$41.44$14.78▼$48.53$2.11B0.29724,930 shs1.08 million shsKODKodiak Sciences$31.05-9.1%$39.92$3.43▼$47.84$1.94B2.21638,104 shs1.45 million shsMLYSMineralys Therapeutics$23.69-5.4%$27.95$12.59▼$47.65$1.95B0.571.55 million shs4.18 million shsZSQRCoeptis Therapeutics$10.12-7.1%$11.93$6.80▼$21.41$520.48M-0.22238,395 shs230,956 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceELVNEnliven Therapeutics-2.20%-12.28%-15.75%+17.90%+55.72%KODKodiak Sciences-9.10%-15.42%-32.34%+24.90%+682.12%MLYSMineralys Therapeutics-5.43%-24.79%-21.35%-10.91%+52.64%ZSQRCoeptis Therapeutics-7.07%+8.70%-27.66%-23.28%+6.75%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceELVNEnliven Therapeutics 2.83Moderate Buy$61.8078.05% UpsideKODKodiak Sciences 2.63Moderate Buy$42.1435.73% UpsideMLYSMineralys Therapeutics 2.63Moderate Buy$49.33108.25% UpsideZSQRCoeptis Therapeutics 1.00SellN/AN/ACurrent Analyst Ratings BreakdownLatest ZSQR, ELVN, KOD, and MLYS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/2/2026ELVNEnliven Therapeutics MizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$45.00 ➝ $62.006/1/2026MLYSMineralys Therapeutics Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold6/1/2026MLYSMineralys Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy5/12/2026ELVNEnliven Therapeutics GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$80.005/11/2026ELVNEnliven Therapeutics GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy5/11/2026KODKodiak Sciences Chardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeNeutral ➝ Buy$14.00 ➝ $61.005/8/2026ELVNEnliven Therapeutics The Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$41.00 ➝ $59.004/27/2026MLYSMineralys Therapeutics TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy4/21/2026MLYSMineralys Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/20/2026ELVNEnliven Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)3/27/2026KODKodiak Sciences UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$50.00 ➝ $80.00(Data available from 6/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookELVNEnliven TherapeuticsN/AN/AN/AN/A$7.74 per shareN/AKODKodiak SciencesN/AN/AN/AN/A$2.97 per shareN/AMLYSMineralys TherapeuticsN/AN/AN/AN/A$8.17 per shareN/AZSQRCoeptis Therapeutics$1.36M382.70N/AN/A$2.63 per share3.85Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateELVNEnliven Therapeutics-$103.69M-$1.67N/AN/AN/AN/A-21.04%-20.41%8/12/2026 (Estimated)KODKodiak Sciences-$229.97M-$4.17N/AN/AN/AN/A-253.85%-81.48%8/12/2026 (Estimated)MLYSMineralys Therapeutics-$154.65M-$2.05N/AN/AN/AN/A-27.92%-26.98%8/11/2026 (Estimated)ZSQRCoeptis Therapeutics-$11.92M-$2.52N/AN/AN/A-810.04%-92.29%-73.52%N/ALatest ZSQR, ELVN, KOD, and MLYS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2026Q1 2026ZSQRCoeptis TherapeuticsN/A-$0.65N/A-$0.65N/A$0.11 million5/7/2026Q1 2026ELVNEnliven Therapeutics-$0.44-$0.38+$0.06-$0.38N/AN/A5/7/2026Q4 2025KODKodiak Sciences-$0.93-$0.94-$0.01-$0.94N/AN/A5/6/2026Q1 2026MLYSMineralys Therapeutics-$0.51-$0.47+$0.04-$0.47N/AN/A3/31/2026Q4 2025KODKodiak Sciences-$1.02-$1.04-$0.02-$1.04N/AN/A3/19/2026Q4 2025ZSQRCoeptis TherapeuticsN/A-$0.12N/A-$0.12N/A$0.86 million3/12/2026Q4 2025MLYSMineralys Therapeutics-$0.57-$0.40+$0.17-$0.40N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthELVNEnliven TherapeuticsN/AN/AN/AN/AN/AKODKodiak SciencesN/AN/AN/AN/AN/AMLYSMineralys TherapeuticsN/AN/AN/AN/AN/AZSQRCoeptis TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioELVNEnliven TherapeuticsN/A40.3240.32KODKodiak SciencesN/A3.543.54MLYSMineralys TherapeuticsN/A44.3344.33ZSQRCoeptis Therapeutics0.013.253.25Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipELVNEnliven Therapeutics95.08%KODKodiak Sciences89.06%MLYSMineralys Therapeutics84.46%ZSQRCoeptis Therapeutics13.88%Insider OwnershipCompanyInsider OwnershipELVNEnliven Therapeutics3.00%KODKodiak Sciences45.90%MLYSMineralys Therapeutics18.94%ZSQRCoeptis Therapeutics24.25%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableELVNEnliven Therapeutics5060.90 million59.08 millionOptionableKODKodiak Sciences9062.58 million33.86 millionOptionableMLYSMineralys Therapeutics2882.50 million66.87 millionOptionableZSQRCoeptis Therapeutics251.43 million38.96 millionNot OptionableZSQR, ELVN, KOD, and MLYS HeadlinesRecent News About These CompaniesZ Squared, Inc. Enters $50 Million Committed Equity Forward Purchase Agreement to Support AI Infrastructure BuildoutJune 4 at 7:05 AM | prnewswire.comZ Squared, Inc. Announces Preliminary Inclusion in Russell 3000® and Russell 2000® IndexesMay 27, 2026 | prnewswire.comVanderbilt Report: Z Squared Locks In Zero-Cash, Zero-Debt Path to 42 MW of AI-Ready PowerMay 26, 2026 | globenewswire.comZ Squared, Inc. Outlines Phase 1 Plan to Reach 100 MW of AI-Ready Infrastructure for Inference WorkloadsMay 19, 2026 | prnewswire.comZ Squared Appoints Jon Najarian, Pete Najarian, Marc LoPresti and Jay Zapata to Newly Formed Advisory BoardMay 4, 2026 | prnewswire.comZ Squared to Acquire Skycore Digital, Adding 24 MW of Energized AI Infrastructure with Expansion Path to 42 MWApril 29, 2026 | prnewswire.comZ Squared, Inc. to Ring the Nasdaq Closing Bell in Celebration of Its Listing on the Nasdaq Global MarketApril 28, 2026 | prnewswire.comCoeptis Therapeutics Announces Approval of Z Squared Inc.'s Nasdaq Listing ApplicationApril 27, 2026 | finanznachrichten.deZ Squared Provides Additional Information on Previously Disclosed Pro Rata DistributionApril 27, 2026 | tmcnet.comCoeptis Therapeutics Receives Shareholder Approval Towards Z Squared MergerApril 27, 2026 | finanznachrichten.deZ Squared Inc.: Z Squared Announces Completion of Business Combination with Coeptis Therapeutics and Listing on the Nasdaq Global MarketApril 25, 2026 | finanznachrichten.deZ Squared Announces Completion of Business Combination with Coeptis Therapeutics and Listing on the Nasdaq Global MarketApril 24, 2026 | prnewswire.comCoeptis Therapeutics: Coeptis Announces Approval of Z Squared Inc.'s Nasdaq Listing ApplicationApril 9, 2026 | finanznachrichten.deWhy Coeptis Therapeutics Holdings, Inc.’s (COEP) Stock Is Up 10.60%April 9, 2026 | aaii.comACoeptis Announces Approval of Z Squared Inc.’s Nasdaq Listing ApplicationApril 7, 2026 | markets.businessinsider.comNasdaq Approves Listing for Coeptis Therapeutics Holdings, Inc. Post-Merger with Z Squared Inc.April 7, 2026 | quiverquant.comQCoeptis Announces Approval of Z Squared Inc.'s Nasdaq Listing ApplicationApril 7, 2026 | globenewswire.comCoeptis Therapeutics: Vanderbilt Report: Coeptis / Z Squared Merger Enters Final Stretch - Closing Imminent as Institutional Tailwinds BuildMarch 9, 2026 | finanznachrichten.deVanderbilt Report: Coeptis / Z Squared Merger Enters Final Stretch - Closing Imminent as Institutional Tailwinds BuildMarch 9, 2026 | finance.yahoo.comCoeptis Therapeutics Pivots from Biotech to Cryptocurrency MiningFebruary 27, 2026 | aktiencheck.deANew MarketBeat Followers Over TimeMedia Sentiment Over TimeZSQR, ELVN, KOD, and MLYS Company DescriptionsEnliven Therapeutics NASDAQ:ELVN$34.71 -0.78 (-2.20%) Closing price 06/5/2026 04:00 PM EasternExtended Trading$34.74 +0.03 (+0.10%) As of 06/5/2026 04:15 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations. The company is headquartered in Boulder, Colorado.Kodiak Sciences NASDAQ:KOD$31.05 -3.11 (-9.10%) Closing price 06/5/2026 04:00 PM EasternExtended Trading$30.46 -0.60 (-1.92%) As of 06/5/2026 07:23 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate to treat retinal diseases with an inflammatory component; and KSI-601, a triplet biopolymer conjugate for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.Mineralys Therapeutics NASDAQ:MLYS$23.69 -1.36 (-5.43%) Closing price 06/5/2026 04:00 PM EasternExtended Trading$23.74 +0.05 (+0.21%) As of 06/5/2026 07:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.Coeptis Therapeutics NASDAQ:ZSQR$10.12 -0.77 (-7.07%) As of 06/5/2026 04:00 PM EasternCoeptis Therapeutics Holdings, Inc., a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy. The company also offers its drugs for acute myeloid leukemia and acute respiratory diseases. Coeptis Therapeutics Holdings, Inc. has co-development agreement Vici Health Sciences, LLC to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson's Disease. The company was founded in 2017 and is headquartered in Wexford, Pennsylvania. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/01 - 06/05 Samsara Just Answered The AI Question—Is Wall Street Ready To Listen? A Lulu of a Miss Sends Lululemon to New Lows—Look Out Below Five Below Down 12% Post Earnings—Is the Selloff Overdone? IREN's 800MW Bet Flips the AI Power Switch Buy the Dip? Broadcom's AI Moat Is Wider Than Ever CrowdStrike Earnings Beat Sparks Selloff—Buy the Dip? The Market Has Ollie’s Bargain Outlet Completely Wrong Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
